EML4 and non-small cell lung carcinoma: ALK inhibitor alectinib, nivolumab and atezolizumab inhibited the growth of alectinib-sensitive, patient-derived EML4-ALK fusion NSCLC cells by 29 ± 14%, 53 ± 15%, 65 ± 13%, respectively.